Empagliflozin May Regresses Carotid Intima-Media Thickness and Epicardial Adipose Tissue Volume in Patients with Type 2 Diabetes Mellitus
Lokman Hekim Health Sciences · 2021
DOI: 10.14744/lhhs.2021.80001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lokman Hekim Health Sciences, 2021. Verfasst von İsa Ardahanli. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Changes in epicardial adipose tissue (EAT) and carotid intima-media thickness (CIMT), which are markers of subclinical atherosclerosis, were investigated in patients with type-2 diabetes mellitus (DM) initiated with empagliflozin.
Methods
Thirty-seven patients with type-2 DM were included in this study. Empagliflozin was administered to all patients within the indication, and EAT and CIMT measurements were performed. After an average of 6 months of treatment, the effects of empagliflozin on EAT and CIMT were evaluated through remeasurements.
Results
The mean age of the study group was 56.95±11.61 years, and 56.8% (n=21) of the participants were women. The mean duration of DM was 8.6±3.3 years. Significant reductions were found in weight, waist circumference, body mass index, and systolic and diastolic blood pressure at the treatment initiation and post-treatment evaluation (p
Zitieren
APA
Ardahanli, İ. (2021). Empagliflozin May Regresses Carotid Intima-Media Thickness and Epicardial Adipose Tissue Volume in Patients with Type 2 Diabetes Mellitus. Lokman Hekim Health Sciences. https://doi.org/10.14744/lhhs.2021.80001
Vancouver
Ardahanli İ. Empagliflozin May Regresses Carotid Intima-Media Thickness and Epicardial Adipose Tissue Volume in Patients with Type 2 Diabetes Mellitus. Lokman Hekim Health Sciences. 2021. doi:10.14744/lhhs.2021.80001
BibTeX
@article{Ardahanli2021,
author = {Ardahanli, İsa},
title = {Empagliflozin May Regresses Carotid Intima-Media Thickness and Epicardial Adipose Tissue Volume in Patients with Type 2 Diabetes Mellitus},
journal = {Lokman Hekim Health Sciences},
year = {2021},
doi = {10.14744/lhhs.2021.80001}
}
EUVIMED